IP Library Granted Patent US 11,649,293
Granted Patent B2
US 11,649,293 · App. 15/776,541 · Granted May 16, 2023

Method for enhancing humoral immune response

Inventor: Tomoyuki Igawa (Shizuoka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
C07K16/2896A61K39/00A61K39/001102A61K39/395A61P35/00A61P37/04C07K16/065C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,649,293
App. No.
15/776,541
Granted
May 16, 2023
Kind
B2
Abstract

The present invention provides methods for producing antibodies against peptides, proteins, or such to which immune tolerance is easily established, by using antigen-binding molecules comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor (TCR) complex-binding domain. The present invention also provides pharmaceutical compositions for use in combination with therapeutic vaccines and agents for enhancing a humoral immune response, each comprising the antigen-binding molecules as active ingredients.

Claims (11)

1. A method for producing an antibody against an immunogen, the method comprising administering to an animal

(a) a bispecific antibody comprising:

(1) two antigen binding domains, wherein a first antigen binding domain binds to human or mouse CTLA4, and a second antigen binding domain binds to human or mouse CD3, wherein the animal is a human or a mouse, respectively; and

(2) a variant human or mouse IgG Fc region having decreased Fcγ receptor-binding activity, respectively, and

(b) the immunogen which is different from the antigens bound by the bispecific antibody,

wherein the first binding domain comprises (i) an antibody variable region comprising the VH of SEQ ID NO: 54 and VL of SEQ ID NO: 55, or (ii) a humanized antibody variable region comprising a VH comprising the 3 complementarity-determining regions (CDRs) of SEQ ID NO: 54 and a VL comprising the 3 CDRs of SEQ ID NO: 55; and

wherein the second binding domain comprises (i) an antibody variable region comprising VH of SEQ ID NO: 61 and VL of SEQ ID NO: 62, or (ii) a humanized antibody variable region comprising a VH comprising the 3 CDRs of SEQ ID NO: 61 and a VL comprising the 3 CDRs of SEQ ID NO: 62.

2. The method for producing an antibody against an immunogen of claim 1 , the method further comprising

culturing a host cell comprising an expression vector comprising a polynucleotide encoding the antibody against the immunogen, wherein the polynucleotide is from the animal which has been immunized, and

collecting the antibody against the immunogen.

3. The method for producing an antibody against an immunogen of claim 2 , wherein the animal is a mouse, and the polynucleotide encodes a chimeric antibody or a humanized antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2018
From: IGAWA, TOMOYUKI
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 046126/0314 →
Priority Claims (1)
JP JP2015-225235 · Nov 18, 2015 · national
Continuity (1)
Related Publication 20190077872A1 · Mar 14, 2019
Cited By (2)
US 12,479,929 US 12,522,669